MedTrace Logo

Study to Investigate the Analgesic Efficacy of a Single Dose of AZD1386

NCT00672646 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2012-06-08

Study results available
· View outcomes & findings →

Summary

The primary aim of this study is to investigate if AZD1386 can relieve the pain induced by the surgical removal of one lower wisdom-tooth. This will be done by comparing the effect of AZD1386 to placebo ("inactive substance") on pain. A number of patients will instead receive the common painkiller naproxen for comparison purposes. Rescue medication, acetaminophen, will be allowed if a need for additional painkillers would arise. A number of patients will receive naproxen as control.

Conditions

Interventions

DRUG

AZD1386

95mg, oral solution, single dose

DRUG

Naproxen

500mg, capsule, single dose

DRUG

Placebo

AZD1386 Placebo oral solution

Sponsors & Collaborators

Principal Investigators

  • Lynn Webster, MD · Lifetree Clinical Research3838 South, 700 East, Suite 202Salt Lake City, Utah 84106, USA

  • Bror Jonzon · AstraZeneca R&D Södertälje, SE-151 85 Södertälje, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00672646 on ClinicalTrials.gov